Bone Marrow Transplantation
Bone Marrow Transplantation
复制标题
DOI：
10.1515/iupac.84.0358
复制
发表时间：
2016
期刊：
影响因子：
--
通讯作者：
Douglas M. Templeton;M. Schwenk;Reinhild Klein;John Duffus
中科院分区：
文献类型：
--
作者：
Douglas M. Templeton;M. Schwenk;Reinhild Klein;John Duffus
造血干细胞移植已发展成为多种危及生命的血液学、肿瘤和免疫学疾病的现代治疗手段。在世界各地，目前有数千名患者在干细胞移植后存活5年以上，并收集了越来越多的长期并发症数据[1，2]。造血干细胞治疗的长期并发症被归类为与方案相关的毒性、免疫缺陷、感染、慢性移植物抗宿主病、骨病、恶性肿瘤复发和继发性恶性肿瘤(表I)。
Hematopoietic stem cell transplantation has evolved into a modern therapeutic modality for variety of life-threatening hematologie, neoplastic and immunologie diseases. Around the world, thousands of patients are currently alive more than five years following stem cell transplantation and increasing data have been collected for the long term complications [1,2]. Long term complications of hematopoietic stem cell therapy are categorized as regimen related toxicity, immunodeficiency, infection, chronic graft-versus host disease, bone disease, relapse of malignancy and secondary malignancies (Table I).